Related Experiment Video
Updated: Jun 18, 2026
03:23
Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
Published on: May 10, 2024
Mepolizumab and eosinophil-mediated disease
1Section of Immunology & Infection, Division of Applied Medicine, School of Medicine & Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK. g.m.walsh@abdn.ac.uk
Current Medicinal Chemistry
|November 26, 2009
Summary
Mepolizumab effectively reduces eosinophils in various diseases, including severe asthma and hypereosinophilic syndrome. While initial asthma trials showed limited clinical benefits, recent studies highlight its efficacy in reducing exacerbations and improving quality of life.
Area of Science:
- Immunology
- Pulmonology
- Gastroenterology
Background:
- Eosinophils are key inflammatory cells implicated in airway, skin, and gastrointestinal diseases.
- Interleukin-5 (IL-5) is crucial for eosinophil development and tissue accumulation.
- Mepolizumab, an anti-IL-5 monoclonal antibody, is investigated for treating eosinophil-driven conditions.
Purpose of the Study:
- To review the clinical development of mepolizumab for eosinophilic diseases.
- To assess mepolizumab's efficacy in various patient populations and conditions.
Main Methods:
- Review of clinical trials and studies involving mepolizumab.
- Analysis of mepolizumab's effects on eosinophil counts, clinical outcomes, and quality of life.
Main Results:
- Mepolizumab significantly reduced blood and sputum eosinophil counts in asthma patients.
- Early asthma trials showed limited impact on airway hyper-reactivity.
- Recent studies demonstrate mepolizumab's effectiveness in reducing exacerbations and improving quality of life in severe, refractory asthma.
- Mepolizumab shows promise in treating hypereosinophilic syndrome and eosinophilic esophagitis.
Conclusions:
- Mepolizumab is a promising therapeutic agent for diseases characterized by eosinophilic inflammation.
- Further research and clinical development are ongoing for mepolizumab in various eosinophilic conditions.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: